Source: Pigment Cell Melanoma Research. Unidade: FCF
Subjects: QUIMIOTERAPIA, MELANOMA, APOPTOSE
ABNT
REBECCA, Vito William et al. Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma. Pigment Cell Melanoma Research, v. 27, n. 3, p. 465-478, 2014Tradução . . Disponível em: https://doi.org/10.1111/pcmr.12227. Acesso em: 27 set. 2024.APA
Rebecca, V. W., Massaro, R. R., Fedorenko, I. V., Sondak, V. K., Anderson, A. R. A., Kim, E., et al. (2014). Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma. Pigment Cell Melanoma Research, 27( 3), 465-478. doi:10.1111/pcmr.12227NLM
Rebecca VW, Massaro RR, Fedorenko IV, Sondak VK, Anderson ARA, Kim E, Amaravadi RK, Maria-Engler SS, Messina JL, Gibney GT, Kudchadkar RR, Smalley KSM. Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma [Internet]. Pigment Cell Melanoma Research. 2014 ; 27( 3): 465-478.[citado 2024 set. 27 ] Available from: https://doi.org/10.1111/pcmr.12227Vancouver
Rebecca VW, Massaro RR, Fedorenko IV, Sondak VK, Anderson ARA, Kim E, Amaravadi RK, Maria-Engler SS, Messina JL, Gibney GT, Kudchadkar RR, Smalley KSM. Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma [Internet]. Pigment Cell Melanoma Research. 2014 ; 27( 3): 465-478.[citado 2024 set. 27 ] Available from: https://doi.org/10.1111/pcmr.12227